- ASX200 is trading 0.11% lower at 7483.20 after lunchtime.
- ClearVue soars 25% this week on order from Japanese greenhouse leader.
- Pfizer COVID-19 vaccine approved for administration in Aussies aged 12+.
The Australian market is trading just 0.11% lower at 7483.20 after lunchtime as strong gains for healthcare companies are offset by heavy losses among tech and consumer discretionary stocks.
Tech stocks are plunging again today led by Appen tumbling more than 7% while Nextdc is also down 4.4% and Link Administration is trading 3.22% lower.
Bitcoin is trading 2.71% lower over the last 24-hours at US$46,935.50 at 1:30pm AEST.
Smart building materials company ClearVue is rallying again today in a week of positive news. The company announced it has received the first order from Japanese greenhouse leader Tomita for its solar photovoltaic (PV) glazing solution, following the signing of an exclusive distribution agreement with Tomita back in April.
Making headlines, Pfizer?s COVID-19 vaccine has been granted full approval for administration in all Australians aged 12 years and over. Australia?s Technical Advisory Group on Immunisation announced the change to the younger age of administration in a bid to combat the growing delta COVID-19 outbreak on the nation?s east coast.
And a new company called LiquiGlide has engineered a bottle that is slippery on the inside to ensure every last drop of liquid products like shampoo and soap are used to reduce environmental waste.